MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Protalix BioTherapeutics Company Profile (NYSE:PLX)

Consensus Ratings for Protalix BioTherapeutics (NYSE:PLX) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.80 (93.88% upside)

Analysts' Ratings History for Protalix BioTherapeutics (NYSE:PLX)
Show:
DateFirmActionRatingPrice TargetActions
4/23/2015Jefferies GroupInitiated CoverageHold -> Buy$2.00 -> $2.60View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2014R. F. LaffertyLower Price TargetBuy$8.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/11/2014Jefferies GroupReiterated RatingHold$4.25 -> $3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2014JPMorgan Chase & Co.Lower Price TargetOverweight$8.00 -> $7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2014Jefferies GroupReiterated RatingHold$5.50 -> $4.25View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/24/2014R. F. LaffertyInitiated CoverageBuy$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/14/2014Jefferies GroupBoost Price Target$5.00 -> $5.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/21/2013JPMorgan Chase & Co.Initiated CoverageOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/4/2013 forward)